Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy

American Journal of Transplantation

Volumn 10, Issue 10, 2010, Pages 2270-2278

  Biancone, L ^a,b   Bussolati, B ^b   Mazzucco, G ^a   Barreca, A ^a   Gallo, E ^a   Rossetti, M ^a   Messina, M ^a   Nuschak, B ^b   Fop, F ^a   Medica, D ^b   Cantaluppi, V ^a,b   Camussi, G ^a,b   Segoloni, G P ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Kidney transplantation; mTOR inhibitor; proteinuria

Indexed keywords

EVEROLIMUS; NEPHRIN; RAPAMYCIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; GLOMERULUS EPITHELIUM; GRAFT RECIPIENT; HUMAN; HUMAN CELL; KIDNEY BIOPSY; KIDNEY GRAFT; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA;

ADULT; AGED; CELLS, CULTURED; HUMANS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MEMBRANE PROTEINS; MIDDLE AGED; PODOCYTES; PROTEINURIA; RETROSPECTIVE STUDIES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77957195889     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03259.x     Document Type: Article

References (29)

1. Kestilä M, Lenkkeri U, Männikkö M et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998 1: 575 582. (Pubitemid 128374693)
2. Patrakka J, Tryggvason K. Nephrin-a unique structural and signaling protein of the kidney filter. Trends Mol Med 2007 13: 396 403. (Pubitemid 47385379)
3. Huh W, Kim DJ, Kim MK et al. Expression of nephrin in acquired human glomerular disease. Nephrol Dial Transplant 2002 17: 478 484. (Pubitemid 34211147)
4. Furness PN, Hall LL, Shaw JA, Pringle JH. Glomerular expression of nephrin is decreased in acquired human nephrotic syndrome. Nephrol Dial Transplant 1999 14: 1234 1237. (Pubitemid 29209313)
5. Doublier S, Ruotsalainen V, Salvidio G et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephritic syndrome. Am J Pathol 2001 158: 1723 1731. (Pubitemid 32422937)
6. Doublier S, Salvidio G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy: Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003 52: 1023 1030. (Pubitemid 36384273)
7. Schena FP. Review of symposium. Sirolimus in kidney transplantation. Transplantation 2009 87 (8 Suppl S30 S33.
8. Konings IR, Verweij J, Wiemer EA, Sleijfer S. The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 2009 9: 439 450.
9. Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of sirolimus therapy. Transplantation 2009 87 (8 Suppl S23 S26.
10. Hochegger K, Wurz E, Nachbaur D, Rosenkranz AR, Clausen J. Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2009 44 (1 63 65.
11. Aliabadi AZ, Pohanka E, Seebacher G et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008 8: 854 861. (Pubitemid 351347752)
12. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005 5: 2318 2323.
13. Diekmann F, Gutiérrez-Dalmau A, López S et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: Comparison of two CNI-free protocols. Nephrol Dial Transplant 2007 22: 2316 2321. (Pubitemid 47244710)
14. Ruiz JC, Diekmann F, Campistol JM et al. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study. Transplant Proc 2005 37: 3833 3835. (Pubitemid 43015183)
15. Van Den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006 70: 1355 1357. (Pubitemid 44435189)
16. Sahin GM, Sahin S, Kantarci G, Ergin H. Proteinuria after conversion to sirolimus in renal transplant recipients. Transplant Proc 2006 38: 3473 3475. (Pubitemid 44908528)
17. Vollenbröker B, George B, Wolfgart M, Saleem MA, Pavenstädt H, Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009 296: F418 F426.
18. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: Mechanisms, significance, and management. Transplant Rev (Orlando) 2008 22: 125 130. (Pubitemid 351372914)
19. Letavernier E, Bruneval P, Vandermeersch S et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009 24: 630 638.
20. Torras J, Herrero-Fresneda I, Gulias O et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: Is it a matter of podocyte damage? Nephrol Dial Transplant 2009 24: 3632 3640.
21. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal pathology: Updates and future directions. Am J Transplant 2008 8: 753 760. (Pubitemid 351347767)
22. Conaldi PG, Biancone L, Bottelli A, De Martino A, Camussi G, Toniolo A. Distinct pathogenic effects of group B coxsackieviruses on human glomerular and tubular kidney cells. J Virol 1997 71: 9180 9187. (Pubitemid 27492359)
23. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 2003 22: 7989 7997. (Pubitemid 37179944)
24. Koop K, Eikmans M, Baelde HJ et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003 14: 2063 2071. (Pubitemid 36909914)
25. Ruiz JC, Campistol JM, Sánchez-Fructuoso A et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006 21: 3252 3257. (Pubitemid 44567102)
26. Liew A, Chiang GS, Vathsala A. Factors associated with proteinuria in renal transplant recipients treated with sirolimus. Transpl Int 2009 22: 313 322.
27. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004 4: 1869 1875. (Pubitemid 39434449)
28. Marx C, Busch M, Ott U, Gerth J, Wolf G. Proteinuria after conversion to sirolimus in kidney transplant recipients: Impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin- receptor antagonists. Clin Transplant 2009, doi:.
29. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007 2: 326 333.